News - Pharmaphorum

Latest News

in News News News

NICE says ‘no’ to Roche’s Perjeta after breast cancer surgery
June 19, 2018 Share
X
NICE says ‘no’ to Roche’s Perjeta after breast cancer surgery
https://pharmaphorum.com/news/nice-says-no-to-roches-perjeta-after-breast-cancer-surgery/
in News News

FDA approves Keytruda in cervical cancer
June 13, 2018 Share
X
FDA approves Keytruda in cervical cancer
https://pharmaphorum.com/news/fda-approves-keytruda-cervical-cancer/

See all

More news

Lung cancer drug Keytruda to become routinely available on NHS

NICE has given the green light for lung cancer drug Keytruda to be used as a routine treatment

Lung cancer drug Keytruda to become routinely available on NHS

https://pharmaphorum.com/news/lung-cancer-drug-keytruda-nhs/

Amgen faces first Neulasta biosimilar rival as FDA approves Mylan drug

Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar

Amgen faces first Neulasta biosimilar rival as FDA approves Mylan drug

https://pharmaphorum.com/news/amgen-neulasta-biosimilar-fda-mylan-fulphila/

ASCO 2018 – Monday 4th June: BMS tries different tack as Merck & Co locks out lung cancer I/O

Merck & Co has dominated proceedings at the American Society of Clinical Oncology (ASCO), with a steady flow

ASCO 2018 – Monday 4th June: BMS tries different tack as Merck & Co locks out lung cancer I/O

https://pharmaphorum.com/event-coverage/asco-2018-bms-merck-co-locks-out-lung-cancer-i-o/

Roche’s Perjeta combo approved in Europe for early breast cancer

The European Commission (EC) has approved Roche’s Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence.

Roche’s Perjeta combo approved in Europe for early breast cancer

https://pharmaphorum.com/news/roches-perjeta-approved-early-breast-cancer/

Bayer and MD Anderson collaborate on novel targeted cancer treatments

Bayer and the University of Texas MD Anderson Cancer Center have signed a five-year collaboration agreement to accelerate the development of novel targeted treatments for cancer.

Bayer and MD Anderson collaborate on novel targeted cancer treatments

https://pharmaphorum.com/news/bayer-md-anderson-novel-targeted-cancer-treatments/

NICE recommends Pfizer’s Xalkori in rare lung cancer

NICE has issued a Final Appraisal Determination that recommends the use of Pfizer’s Xalkori (crizotinib) in England under the Cancer Drugs Fund (CDF) for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).

NICE recommends Pfizer’s Xalkori in rare lung cancer

https://pharmaphorum.com/news/nice-pfizers-xalkori-rare-lung-cancer/

AZ’s Imfinzi hits second lung cancer trial goal

But AZ is anxiously waiting for results of MYSTIC trial

AZ’s Imfinzi hits second lung cancer trial goal

https://pharmaphorum.com/news/azs-imfinzi-hits-second-lung-cancer-trial-goal/

Merck & Co’s Keytruda could catch BMS’ rival with new lung cancer use

Merck & Co’s Keytruda blockbuster immunotherapy could have yet another use, after it significantly boosted survival in patients

Merck & Co’s Keytruda could catch BMS’ rival with new lung cancer use

https://pharmaphorum.com/news/merck-keytruda-bms-opdivo-lung-cancer-use/

US lawmakers back ‘right to try’ legislation

US lawmakers have approved new laws giving terminally ill patients the “right to try” unapproved drugs if there

US lawmakers back ‘right to try’ legislation

https://pharmaphorum.com/news/us-lawmakers-back-right-to-try-legislation/

Nektar, BioMarin, and Alnylam top list of biotech M&A targets

With Takeda’s £46 billion acquisition of Shire, it’s been a busy year for pharma M&A – and according

Nektar, BioMarin, and Alnylam top list of biotech M&A targets

https://pharmaphorum.com/news/nektar-biomarin-and-alnylam-top-list-of-biotech-ma-targets/

AstraZeneca feels pain as sales slump continues

First quarter results from AstraZeneca have disappointed investors, sending shares down on the London Stock Exchange, as the

AstraZeneca feels pain as sales slump continues

https://pharmaphorum.com/news/astrazeneca-feels-pain-as-sales-slump-continues/

EU approves Ipsen’s Cabometyx in first line kidney cancer

Drug looks set to become core part of Ipsen’s cancer offering

EU approves Ipsen’s Cabometyx in first line kidney cancer

https://pharmaphorum.com/news/eu-approves-ipsens-cabometyx-in-first-line-kidney-cancer/

Moderna and Merck expand partnership to develop new cancer vaccines

Moderna and Merck & Co have expanded their partnership to develop and commercialise novel personalised messenger RNA (mRNA)

Moderna and Merck expand partnership to develop new cancer vaccines

https://pharmaphorum.com/news/moderna-and-merck-expand-partnership-to-develop-new-cancer-vaccines/

Lilly buys cancer biotech ARMO for $1.6bn

Lilly adds pancreatic cancer drug to pipeline

Lilly buys cancer biotech ARMO for $1.6bn

https://pharmaphorum.com/news/lilly-buys-cancer-biotech-armo-for-1-6bn/

NHS cuts clinical trial bureaucracy

NHS chiefs have introduced new arrangements to fast track clinical trials and improve patients’ access to cutting-edge therapies.

NHS cuts clinical trial bureaucracy

https://pharmaphorum.com/news/nhs-moves-to-cut-clinical-trials-bureaucracy/

Search

Advanced Search

Trending

Latest News

More news